Skip to main content
Journal cover image

Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.

Publication ,  Journal Article
Urba, SG; Chansky, K; VanVeldhuizen, PJ; Pluenneke, RE; Benedetti, JK; Macdonald, JS; Abbruzzese, JL; Southwest Oncology Group Study,
Published in: Invest New Drugs
January 2004

PURPOSE: Experimental data, both in vivo and in vitro, suggest that the combination of gemcitabine and cisplatin acts synergistically. Within the Southwest Oncology Group, we designed a Phase II trial to test this chemotherapy combination for patients with esophageal cancer. EXPERIMENTAL DESIGN: Patients with metastatic or recurrent esophageal cancer were treated with gemcitabine 1000 mg/m(2) on days 1, 8, and 15, and cisplatin 100 mg/m(2) on day 15. Cycles were repeated every 28 days. The statistical endpoint was overall survival. RESULTS: Sixty-four eligible patients were accrued from 37 institutions. Twenty-six percent of patients had prior chemotherapy. The treatment was generally well-tolerated, with the most common toxicity being neutropenia in 31% of patients. All 64 patients have died. Survival at 3 months was 81%, and at 1 year was 20%. Median survival was 7.3 months. CONCLUSIONS: This regimen is tolerable palliative option for patients with metastatic esophageal cancer.

Duke Scholars

Published In

Invest New Drugs

DOI

ISSN

0167-6997

Publication Date

January 2004

Volume

22

Issue

1

Start / End Page

91 / 97

Location

United States

Related Subject Headings

  • Survival Rate
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Humans
  • Gemcitabine
  • Female
  • Esophageal Neoplasms
  • Deoxycytidine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Urba, S. G., Chansky, K., VanVeldhuizen, P. J., Pluenneke, R. E., Benedetti, J. K., Macdonald, J. S., … Southwest Oncology Group Study, . (2004). Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. Invest New Drugs, 22(1), 91–97. https://doi.org/10.1023/b:drug.0000006179.20974.af
Urba, Susan G., Kari Chansky, Peter J. VanVeldhuizen, Robert E. Pluenneke, Jacqueline K. Benedetti, John S. Macdonald, James L. Abbruzzese, and James L. Southwest Oncology Group Study. “Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.Invest New Drugs 22, no. 1 (January 2004): 91–97. https://doi.org/10.1023/b:drug.0000006179.20974.af.
Urba SG, Chansky K, VanVeldhuizen PJ, Pluenneke RE, Benedetti JK, Macdonald JS, et al. Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. Invest New Drugs. 2004 Jan;22(1):91–7.
Urba, Susan G., et al. “Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.Invest New Drugs, vol. 22, no. 1, Jan. 2004, pp. 91–97. Pubmed, doi:10.1023/b:drug.0000006179.20974.af.
Urba SG, Chansky K, VanVeldhuizen PJ, Pluenneke RE, Benedetti JK, Macdonald JS, Abbruzzese JL, Southwest Oncology Group Study. Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. Invest New Drugs. 2004 Jan;22(1):91–97.
Journal cover image

Published In

Invest New Drugs

DOI

ISSN

0167-6997

Publication Date

January 2004

Volume

22

Issue

1

Start / End Page

91 / 97

Location

United States

Related Subject Headings

  • Survival Rate
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Humans
  • Gemcitabine
  • Female
  • Esophageal Neoplasms
  • Deoxycytidine